DexCom, Inc. (NASDAQ:DXCM) Shares Sold by MetLife Investment Management LLC

MetLife Investment Management LLC trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 1.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,567 shares of the medical device company’s stock after selling 1,844 shares during the period. MetLife Investment Management LLC’s holdings in DexCom were worth $9,376,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in DexCom during the third quarter worth approximately $1,020,000. Pine Valley Investments Ltd Liability Co boosted its holdings in shares of DexCom by 59.2% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company’s stock worth $381,000 after purchasing an additional 2,111 shares during the last quarter. World Investment Advisors LLC purchased a new stake in shares of DexCom in the third quarter valued at $2,351,000. Wilmington Savings Fund Society FSB acquired a new position in DexCom in the third quarter valued at $381,000. Finally, Tidal Investments LLC lifted its position in DexCom by 68.0% during the third quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company’s stock worth $2,463,000 after buying an additional 14,872 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Down 3.6 %

Shares of DXCM opened at $66.11 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a one year low of $57.52 and a one year high of $139.24. The stock has a 50-day moving average price of $74.62 and a 200 day moving average price of $76.74. The company has a market capitalization of $25.92 billion, a P/E ratio of 46.23, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of research analyst reports. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group upped their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Citigroup lifted their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Morgan Stanley upped their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Insider Transactions at DexCom

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,009 shares of company stock valued at $8,044,178. Insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.